spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Owlstone Medicals ReCIVA Named Invention of the Year in Top 50 Digital Health Awards

Owlstone Medical

Awards recognize exceptional progress in bringing technological advancements to healthcare

Cambridge, UK, December 6, 2016: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards.

Each year ahead of the JP Morgan Health Conference in San Francisco, fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank. Within the Top 50, a number of individuals and organizations are awarded through public nominations and votes from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system.

Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with the Field Asymmetric Ion Mobility Spectrometer (FAIMS) sensor platform, to accurately and selectively detect targeted biomarkers of disease in breath (and other bodily fluids).

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are delighted that ReCIVA has been named Invention in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.”

To find out more about Owlstone Medical visit: www.owlstonemedical.com; for more information on 2017 Top 50 in Digital Health visit www.rockhealth.com/announcing-the-winners-of-the-2017-top-50-in-digital-health/
phone +44 (0)1223 428200
web www.owlstonenanotech.com
email Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

MRC Technology monetises royalties on cancer drug Keytruda (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital


More info >>


White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement